Are lopinavir and efavirenz serum concentrations in HIV-infected children in the therapeutic range in clinical practice?

Autor: Bibra, Mirjam von, Rosenkranz, Bernd, Pretorius, Erina, Rabie, Helena, Edson, Claire, Lenker, Ulrike, Cotton, Mark, Klinker, Hartwig
Předmět:
Zdroj: Paediatrics & International Child Health; May2014, Vol. 34 Issue 2, p138-141, 4p, 1 Chart, 1 Graph
Abstrakt: Background: In antiretroviral treatment the role of therapeutic drug monitoring via measurement of serum levels remains unclear, especially in children. Aim: To quantify exposure to LPV and EFV in children receiving therapy in a routine clinical setting in order to identify risk factors associated with inadequate drug exposure. Method: A prospective study was conducted in a routine clinical setting in Tygerberg Children's Hospital, South Africa. A total of 53 random serum levels were analyzed. Serum concentrations were determined by an established high-performance liquid chromatography method. Results: Of 53 HIV-infected children treated with lopinavir (n = 29, median age 1·83 y) or efavirenz (n = 24, median age 9·3 years), 12 showed serum levels outside the therapeutic range (efavirenz) or below Cmin (lopinavir). Low bodyweight, rifampicin co-treatment, and significant comorbidity were potential risk factors for inadequate drug exposure. Conclusion: These findings, together with previous studies, indicate that therapeutic drug monitoring can improve the management of antiretroviral therapy in children at risk. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje